European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) was established in 1993. Inaugurated in Lisbon in 1995, it is one of the EU’s decentralised agencies. The EMCDDA exists to provide the EU and its Member States with a factual overview of European drug problems and a solid evidence base to support the drugs debate. Today it offers policymakers the data they need for drawing up informed drug laws and strategies. It also helps professionals and practitioners working in the field pinpoint best practice and new areas of research.

Mission

The EMCDDA was set up to provide 'factual, objective, reliable and comparable information concerning drugs, drug addiction and their consequences'

European Drugs Summer School

Lisbon, Portugal,

The 2020 edition of the 'Summer school on illicit drugs Europe' will take place from 29 June-10 July 2020. 

Monitoring the Elimination of Viral Hepatitis as a Public Health Threat in Europe

Published by
EMCDDA

This technical report focuses on an elimination barometer for viral hepatitis to help countries assess progress towards eliminating hepatitis C and B among people who inject drugs (PWID).

The barometer is being developed by the EMCDDA together with its expert network on drug-related infectious diseases (DRID), as a follow-up to the first global health sector strategy on viral hepatitis endorsed by the World Health Assembly in 2016.

Prevention of Drug-Related Deaths

Published by
EMCDDA

Opioids are a class of drugs that act on the nervous system to produce feelings of pleasure and pain relief. Opioids have a high potential for causing addiction in some people and can cause life-threatening health problems, including the risk of overdose.

Over the years there has been a dramatic rise in the number of drug-related deaths worldwide. Finding ways to tackle the issue has become a public health priority.